New Protein Target Could Reverse Breast Cancer Resistance
Lab research shows how breast cancer cells export chemotherapy drugs and suggests a new way to potentially block that process.
Updated on Oct. 16, 2026 in Cancer
Researchers have identified a mechanism by which breast cancer cells develop resistance to the chemotherapy drug paclitaxel. The study, conducted in laboratory models, reveals that targeting a specific protein interaction could potentially reverse this resistance.
Why it matters
Understanding how cancer cells export chemotherapy drugs is critical for improving treatment efficacy. This finding identifies a specific protein pathway that, if effectively targeted, might overcome common drug-resistance challenges in breast cancer therapy.
In an in vitro study, researchers demonstrated that the phosphorylation of Aurora kinase B at the S227 residue regulates its movement within cancer cells. These preliminary findings provide a mechanistic basis for how cells survive chemotherapy treatments.
The details
Breast cancer cells can resist paclitaxel by pumping the drug out of the cell, a process mediated by RAB27B protein. When Aurora kinase B (AURKB) is phosphorylated at the S227 site, it moves into the cytoplasm and stabilizes RAB27B, facilitating this drug export. Hesperadin, a selective inhibitor, prevents this interaction, trapping the drug-exporting machinery and potentially re-sensitizing the cancer cells to chemotherapy.
Timeline
October 16, 2026: Article publication date.
Health Landscape
This research advances our understanding of taxane-based chemotherapy resistance, a persistent challenge in oncology. It sits within a broader scientific effort to map the signaling pathways that allow tumor cells to survive standard therapeutic interventions.
This study is an early-stage discovery and does not change current treatment protocols or offer new clinical options. Patients concerned about chemotherapy resistance should discuss specific concerns or potential participation in clinical trials with their oncology team.
The takeaway
Breast cancer cells can use specific protein pathways to export chemotherapy drugs like paclitaxel. Always consult your oncologist to understand your specific cancer profile and to discuss whether clinical trials for new treatment strategies might be relevant to your care.
Further reading
For more information on how researchers are working to improve outcomes for patients, visit our Cancer section.
Source note: This article includes information reported by Alwasat-ye.
